Last week we hosted a Genesis fringe event to discuss the highly topical issue of anti-microbial resistance. The meeting was held as part of a series of satellite seminars hosted in London on the day prior to the Genesis conference. The debate considered radically changing the treatment of anti-microbial resistant infections, and whether there is a business case, and was led by Martin MacLean alongside speakers from Public Health England, AMR Centre, Instinctif Partners, New Wave Ventures and Cantor Fitzgerald.